Projects
Search from 1164 projects:
1164 Project(s)
SAKK 21/18 Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A mul-ticenter, randomized phase III trial
Jun 25, 2019Breast cancer is the most frequent malignancy in women and the leading cause of cancer mortality in most countries in Europe. Metastatic breast cancer remains an incurable disease with a median overall survival (OS) of 2–4 years and a 5 year surviv...
Clinical Studies - Jun 25, 2019 - Dec 31, 2026
Ongoing
Project leader: Hasler-Strub Ursula
A multicentre randomised phase III trial comparing atezolizumab
Jun 20, 2019Evaluation einer Immuntherapie in der ersten Therapielinie in Kombination mit einer Standard Chemo-/Avastintherapie bei Patienten mit malignem Mesotheliom
Clinical Studies - Jun 20, 2019 - Jul 4, 2025
Ongoing
Project leader: Früh Martin
Multi-omic Approach with Genome editing to unravel the Resistance Mechanisms to Ceftazidime Avibactam in Pseudomonas aeruginosa,
Jun 20, 2019In this study, a collaborative work with EMBL Heidelberg, ETH- D BSSE Empa (Materials Science and Technology), we deciphered –hitherto unknown- resistance mechanisms of P. aeruginosa to ceftazidime- avibactam (CZA), a novel antibiotic with a multi-o...
Fundamental Research - Jun 20, 2019 - Jan 1, 2023
Automatically Closed
Project leader: Babouee Flury Baharak, Kogadeeva-Zimmermann Maria
SAKK 95/17:
Jun 17, 2019After tumor removal, patients with hormone receptor posi-tive breast cancer often receive adjuvant endocrine treat-ment, with the use of an aromatase inhibitor (AI) being standard of care in the population of postmenopausal women. Common side effects...
Fundamental Research - Jun 17, 2019 - Aug 2, 2024
Automatically Closed
EORTC 1702-LCG-ROG Targeted therapy with or without dose-intensified radiotterapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors
Jun 12, 2019Targeted therapy beyond Progression with or without dose-intensified radiotHerapy in oligo-progressive disease (OPD) in oncogene Addicted Lung Tumors (HALT) Objectives: To determine wether in patients with Mutation positive advanced NSCLC the use of...
Clinical Studies - Jun 12, 2019 - Feb 1, 2021
Automatically Closed
Project leader: Glatzer Markus
IELSG-45: Randomized Phase II Trial on Fitness- and Comorbidity- Tailored Treatment in Elderly Patients with Newly Diagnosed Primary CNS Lymphoma (FIORELLA Trial)
Jun 7, 2019Primary central nervous system lymphomas (PCNSL) are rare aggressive malignancies, mostly of B-cell origin, representing 4% of intracranial neoplasms and 4-6% of extranodal non-Hodgkin's lymphomas (NHL). Despite improvements in treat-ment, PCNSL is a...
Clinical Studies - Jun 7, 2019 - Jun 27, 2024
Automatically Closed
STORM: A randomized phase II Trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases
Jun 1, 2019To compare metastases-free survival (MFS) between metastasis-directed therapy and metastases-directed therapy with whole pelvis radiotherapy for oligorecurrent nodal prostate cancer. Target: 178 Patients
Clinical Studies - Jun 1, 2019 - Jul 1, 2025
Ongoing
Project leader: Putora Paul Martin
Akupunktur bei chemotherapieinduzierter Dysgeusie – eine randomisierte kontrollierte Studie
Jun 1, 2019Geschmacksstörungen (Dysgeusie) während einer Chemotherapie aufgrund einer Krebserkrankung sind häufig und beeinträchtigen die Lebensqualität erheblich. Bisher gibt es keine wirksamen Behandlungsmassnahmen. In einer randomisierten, kontrollierten, ve...
Clinical Studies - Jun 1, 2019 - Dec 31, 2024
Ongoing
Project leader: Schlaeppi Marc
Protocol SAKK 19/18
May 29, 2019Diese nicht-randomisierte klinische Studie untersucht den oralen FGFR-Inhibitor Rogaratinib in PatientInnen mit fort-geschrittenem nicht-kleinzelligem Bronchialkarzinom und plattenepithelialer Differenzierung. Alle PatientInnen haben vorgängig eine S...
Clinical Studies - May 29, 2019 - Mar 29, 2021
Automatically Closed
Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbes-serung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Dec 17, 2023
Automatically Closed
Project leader: Jörger Markus
Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einige...
Clinical Studies - May 2, 2019 - Aug 30, 2023
Automatically Closed
Project leader: Jörger Markus
ENIGMA: Open label, non-randomized, Phase IB study to character-ize safety, tolerability and recommended dose of EDO-S101, a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic melanoma
May 2, 2019Neuere Immuntherapien zur Behandlung des fortgeschrit-tenen, metastasierten Melanoms haben zu einer Verbesse-rung des Gesamtüberlebens geführt. Diese Immuntherapien führen zu einer Verstärkung der natürlichen Krebsabwehr durch das Immunsystem. Einig...
Clinical Studies - May 2, 2019 - Dec 31, 2024
Ongoing
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
MSD-MK-3475 KEYNOTE 937
May 1, 2019A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant herapy in Participants ith Hepatocellular Carcinoma and Complete Radiological Response after Surgical esection or Local...
Clinical Studies - May 1, 2019 - May 1, 2026
Ongoing
Project leader: Semela David
Members: Stillhard Roman
Peace-4
Apr 26, 2019Prostate cancer is the most frequent cancer in Western countries and castrate- resistant prostate cancer (CRPC) is its lethal form. Survival for CRPC patients with metastases now encompasses 30 months, while that for patients without metastases is ab...
Clinical Studies - Apr 26, 2019 - May 6, 2027
Ongoing
Project leader: Omlin Aurelius
A Phase 3 Study Comparing Daratumumab, VELCADE (borte-zomib), Lenalidomide, and Dexamethasone (D-VRD) vs VELCADE, Lenalidomide, and Dexamethasone (VRD) in Sub-jects with Previously Untreated Multiple Myeloma who are Eligi-ble for High-dose Therapy
Apr 18, 2019This is a randomized, open-label, multicenter study evalu-ating subjects with newly diagnosed multiple myeloma who are deemed eligible for high-dose therapy. Approximately 690 subjects will be stratified by International Staging Sys-tem (ISS) Stage I...
Clinical Studies - Apr 18, 2019 - Dec 1, 2029
Ongoing
Project leader: Silzle Tobias
Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
Apr 15, 2019Kombination von Nivolumab mit dem anti-IL8 monoklona-len Antikörper BMS-986253 in PatientInnen mit selektierten fortgeschrittenen soliden Malignomen und erhöhten IL-8 Blutspiegeln.
Clinical Studies - Apr 15, 2019 - Dec 31, 2020
Automatically Closed
Project leader: Jörger Markus
OPTIMIZE
Apr 8, 2019Prospektive nicht-interventionelle Studie zur optimierten Behandlung einer therapierefraktären Hypercholesterinämie bei Patienten mit heterozygoter familiärer Hypercholesterinämie oder klinisch manifester atherosklerotischer kardiovaskulärer Erkranku...
Clinical Studies - Apr 8, 2019 - Jan 15, 2021
Completed
Project leader: Rickli Hans
Members: Gemperle Michaela
Abbvie M16-852 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and
Apr 2, 2019Giant Cell Arteritis: Phase 3 Safety and Efficacy Study of Upadacitinib in Subjects with Giant Cell Arteritis
Clinical Studies - Apr 2, 2019 - Dec 31, 2024
Ongoing
Project leader: Rubbert-Roth Andrea
Members: Hutz Carina Liane, Bartz-Batliner Mira, Neumann Thomas, Peischl Riana, Sasselli Clelia
Flex Nav
Mar 22, 2019This CE Mark study is a prospective, multi-center, single-arm investigational study to support commercialization of the FlexNav™ Delivery System and Loading System in Europe. The design of this clinical investigation is in compliance to ISO standards...
Clinical Studies - Mar 22, 2019 - Mar 30, 2021
Completed
Project leader: Haager Philipp
Members: Vetsch Susanne
Nano-Architected Metal Oxide Coatings for Implants
Mar 1, 2019tbd
Fundamental Research - Mar 1, 2019 - Dec 31, 2020
Automatically Closed
Project leader: Grob Karl